Retatrutide is an exciting GLP-1 drug that has explosive potential.

BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...

The gap may be too hard to close in the next 12 months.

Both companies may succeed in this industry.

More than 4,400 lawsuits have been filed since millions of Americans embraced GLP-1 drugs like Ozempic, Wegovy and Mounjaro ...

People taking Eli Lilly’s next-generation GLP-1 obesity drug retatrutide shed more pounds than any other weight-loss drug during a late-stage trial, the company said Thursday. Patients using the ...

Eli Lilly working Humana to distribute obesity medications through employer-focused programs via CenterWell Pharmacy.

Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. Over the past few years, Eli Lilly (NYSE: LLY) has ...

Popular weight-loss drugs shouldn't carry suicide warnings, FDA says - Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their blo ...

Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.

Eli Lilly is tackling a high-growth market: weight loss. The company’s weight loss portfolio brought in $10 billion in the ...